Newly Approved Agent Fills Gap in Therapy for High-Risk AML

The US Food and Drug Administration recently approved a new agent for  treatment of adult patients with relapsed or refractory acute myeloid leukemia. (Source: CancerNetwork)

from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2Em7RUC
via IFTTT